T HERE have heen on I\' limited investIgations on the influence of HLA match on organ transplant outcome in African-Americans.l.~ To ohtain this information, a multivariate analysis was performed of 31.291 cases of primarv cadaver kidney transplantation reported to the UNOS Scientific Registry between 1991 and 1995 .. ' The collection included 8111 African-Americans. for whom follow-up was to January I. 1997. The study involved a triple university collaboration involving experts in clinical transplantation. histocompatibilirv. and biostatistical methodology.
HLA MATCHING
The Pittsburgh experience was excluded from the UNOS analysis and reported separatc1y.l hecause tacrolimus was routinely given during the period of case accrual. Nevertheless, 3.2% of the UNOS patients at other centers were treated with tacrolimus: 2.5% of the 8111 African-Americans and 3.4% of the 23.180 .. all others."
In the total collection of 31.291 cases. I-year graft survival with a zero mismatch was 89%. This fell by 3% to 86% with a single mismatch at either the A. B, or DR locus. Within the full range of one to six mismatches. 4% more were lost. As reported in detail elsewhere,3 the small graft survival differences were statistically significant.
But how significant were these survival differences clinically? Part of the answer came from the distribution profile (Tahle 1). Only 174 (or 2.1 %) of the 8111 African-Americans received a zero-mismatched kidnev. compared to 9.90/r in the 23.180 "all-other" population. At the other end of the matching scale. an additional 55R African-Americans (or 0.9%) received a six antigen (full-house) mismatch. Thus. 
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.2";' of the African-American recipients werc in the one to five mismatch spectrum. which also bracketed more than 85<;,( of the "all other" cases ( Table I) .
The graft survival in African-Americans at the I-year posttransplant milestone was not markedly lower than that of the "all other" population at any of the HLA mismatch levels. More relevant to the primary objective of our study. the degree of HLA mismatch had very linle effect on I-year African-American outcome. One-year allograft survival from the top to bottom of the one to live HLA mismatch range varied by less than 2'7r ( Table 2 ). The lack of a stepwise effect also was evident in the one to five mismatch range of the "all other" population. where the I-year survival did not vary by as much as 3% (Table 2) .
By 3 years. graft survival in African-Americans had become inferior to the "all others" ( HL4. (Table 2 ) was essentially the same.
All Others mismatches
although there was a small effect from the fifth to the sixth mismatch. At all levels of HLA mismatch. however, the principal and relative separation of curves had already occurred by the end of the first year (Table 2) . Although the percentages were slightly different in the 23.180 "all other" cases, the overall picture was much the same. Relative risks of graft failure in "al\ other" than AfricanAmerican recipients based on cumulative HLA mismatches using one HLA mismatch population as the reference (1,0), The reference hazard ratio for cyclosporine was provided by tacrolimus,
In Figure I . the hazard ratio (or relative risk) over the first 3 years with various degrees of mismatch in AfricanAmericans (left) or in all others (right). was calculated using the zero HLA mismatch as the reference standard of 1.0, The principal adverse effect came with the first mismatch. which for the African-Americans increased the relative risk of graft loss within 3 years to a modest 1.2. However. the relative risk only increased further to 1.3 from one to five mismatches. For the "all other"" population (Fig   1. right) , the relative risk between one and five mismatches rose from 1.2 to 1.5.
It has been known for more than 25 vears that the absence of an HLA incompatibility (zero ~ismatch or six antigen mismatch) confers a graft survival advantage:'" The practical question is what is the effect of various levels of mismatch, Consequently. the relative risk of cumulative mismatches was recalculated using the one HLA mismatch as the reference standard of 1,0, The relative risk for both African-American and the "'all other"" patients with a zero mismatch was then 0,83 (Figs 2 and 3) . The relative risk in the spectrum of one to five mismatches that encompassed 9 I. 2 (;{, of all African-American recipients increased onl\ from 1.0 to 1.08 (Fig 2) , This was less than the condition pe'r se of being African-American versus "all other"" (relative (Fig 2) , In the ""all other" population (Fi~:;). the rciativc risk fl)Sl' unl\' lrom the relen:nce of 1.(1 provided hv the Slll!.!1e HL\ lllism;ltch to 1.2; with live mismatches. :·\s with ',-\iric;llI-:\mericans. thiS increasc in risk oj graft loss over a 3-year period was less than what incurred with choice of cyclosporine-hased immunoslIppression (I.-L') verSlIS tacrolimus
CREG MATCHING
Because it has been suggested that matching of cross reactive antigen groups (the so-called CREGs or public determinants) can be more discriminatinl!,',,7 we examined the eflcct of the CREG match in the 31.2y I UNOS cases, The computer program of Takemoto et ai" was used to convert the conventional HL\ phenotypes to CREGs,
We began with a distrihution study ( Table 3) . Because CREG matching is directlv derived from HLA phenotypes. the 2460 zero HLA mismatched UNOS cases were by definition also CREG matched (a IOWI{ yield), Howeve~.
with the succession from one to four HLA mismatches. the CREG match yield fell to 35'/C. 10<:;'.2,50. and less than I % in the respective tiers. There were no CREG matches in the five and six HLA mismatched categories ( Table 3) ,
The overall yield of CREG matches from the one to five HLA population in which 90<;( of the UNOS recipients fell was only 3.6':0. The~e CREG-matched organs had gone to only 3,2% of the 7937 African-Americans ~ho did n~t get a zero HLA mismatched kidnev (Table 4 ), The vield rate was onlv 4.3% of the comparable' 20.894 "all othe~s" (Table 4 l, The next question was whether the CREG-matched kidneys were associated with an improved graft survival in the miniscule fraction of the patients in which thev were used. This analysis is heing reported in detail cise~herC."' Interpretation of the results in the African-American recipients was undermined hv inexplicable findings. The 81 CREG-matched patients from the one HLA mismatch tier (Table 4 ) had a nearl\' 10':( higher graft survival at 3 years than the 174 zero HLA misma;ched-patients (Table I ; who hy definition also were CREG matched. Survival should have been essentiallv the same, In addition. CREG mismatched patients from the pooled two to four HLA incom- patlbility tIers actually did better than patlellts who were CREG matched.' In the "all other"' population. no distinctioll could be made between the CREG matched and mismatched patients in any of the one to four HLA defined tiers. all of which had graft survival below the zero HLA mismatch standard. as expected.'
DISCUSSION AND CONCLUSIONS
Three conclusions are justified about the use of HLA matching as an instrument of organ distribution. First. short of a zero mismatch. allocation of primary cadaver kidneys by graded HLA incompatibility scoring has little effect on overall short-or long-term graft survival. Second, the current allocation policies prejudice the candidacy of African-Americans and other hard-to-match populations. Third, tacrolimus-based immune suppression influenced outcome more than the cumulative effect of all HLA mismatches beyond the first one.
There was no clear evidence that CREG matched primary cadaver kidney allografts survived better than CREG mismatched kidneys (reported elsewhere'). Furthermore.
SCANTLEBURY GJERTSON. ELlASZIW ET AL
the distribution studv descrihed showcd that CREG match· ing. even if predictIve of outcome. would not correct organ allocation inequities. Theretore. prospective matching trials either arc not justified or must be viewed as Helsinki Declaration Type I (acquisition of human knowledge) experiments. Such experiments must not be done without informed consent. specificd analyses. and conditions of trial stoppage.
